{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:48:57Z","timestamp":1780940937344,"version":"3.54.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To better understand the patient experience with neuromyelitis optica spectrum disorder (NMOSD) through the course of the illness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>NMOSD is a rare autoimmune disorder that causes recurrent inflammatory attacks of the optic nerve, spinal cord, and brain. Knowledge and awareness of NMOSD in the general medical community are often limited, resulting in potential delays in diagnosis and treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design\/methods<\/jats:title><jats:p>We developed a comprehensive 101-question survey to understand the patient's perspective on their journey from initial presentation to present condition. The survey covered basic demographics, symptoms, medical tests used to reach a diagnosis, and the patient's psychosocial responses to their diagnosis. The survey included questions to determine internal consistency in responses. We shared the survey with members of the Neuromyelitis Optica (NMO) Clinic Facebook group and received responses from 151 patients. All data collected were self-reported and presented as summary statistics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The majority of survey responses were from patients who were female (83%) and White (76%), Asian (7%), or African American (7%). Initial symptoms of disease included fatigue, pain, stiffness\/spasticity, bladder and bowel dysfunction, cognitive\/emotional symptoms, and visual disturbances. Initial reactions to NMOSD diagnosis were frequently fear, anxiety, and\/or depression. Mean (SD) time to diagnosis was 2.2 (3.2) years. First contact with a medical professional was felt to be not helpful or somewhat helpful for many patients (71%), in part due to uncertain diagnosis and\/or treatment. However, once referred to specialists (primarily neurologists), the majority of patients (87%) reported finding a professional who could help. Tests leading to diagnosis included magnetic resonance imaging, lumbar puncture, and blood tests for autoantibodies including aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG). While approximately 30% of patients still felt challenged for a variety of reasons, most patients reported that having a diagnosis and being under the care of a specialist contributed to a comprehensive plan with hope for their future.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The NMOSD patient journey frequently begins with anxiety, fear, and frustration. Finding the right specialist and identifying appropriate screening tests can lead to earlier diagnosis and progression toward better patient outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.966428","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T15:49:32Z","timestamp":1662479372000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["The patient journey with NMOSD: From initial diagnosis to chronic condition"],"prefix":"10.3389","volume":"13","author":[{"given":"Guillermo","family":"Delgado-Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Lapidus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Talero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fped.2020.00339","article-title":"Pediatric NMOSD: a review and position statement on approach to work-up and diagnosis","volume":"8","author":"Tenembaum","year":"2020","journal-title":"Front Pediatr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1212\/NXI.0000000000000583","article-title":"Collaborative international research in clinical and longitudinal experience study in NMOSD","volume":"6","author":"Cook","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler."},{"key":"B8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s00415-021-10665-9","article-title":"NMOSD and MS prevalence in the indigenous populations of Australia and New Zealand","volume":"269","author":"Bukhari","year":"2022","journal-title":"J Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"460825","DOI":"10.1155\/2012\/460825","article-title":"Neuromyelitis optica: an antibody-mediated disorder of the central nervous system","volume":"2012","author":"Oh","year":"2012","journal-title":"Neurol Res Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis\u2014a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","article-title":"Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica","volume":"65","author":"Misu","year":"2005","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/jim-2019-001126","article-title":"CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease","volume":"68","author":"Rosenthal","year":"2020","journal-title":"J Investig Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"21962","DOI":"10.1038\/s41598-021-01294-3","article-title":"Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder","volume":"11","author":"Tradtrantip","year":"2021","journal-title":"Sci Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.msard.2017.08.005","article-title":"Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: a multicenter cohort study","volume":"17","author":"Kessler","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-021-01712-3","article-title":"Comparative Study of AQP4-NMOSD, MOGAD and Seronegative NMOSD: a single-center belgian cohort","author":"Dauby","year":"2021","journal-title":"Acta Neurol Belg."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1468-0009.2005.00409.x","article-title":"Contribution of primary care to health systems and health","volume":"83","author":"Starfield","year":"2005","journal-title":"Milbank Q."},{"key":"B19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3390\/clinpract11040106","article-title":"Bridging the gap between ophthalmology and emergency medicine in community-based emergency departments (EDs): a neuro-ophthalmology guide for ED practitioners","volume":"11","author":"Thomas","year":"2021","journal-title":"Clin Pract."},{"key":"B20","article-title":"\u201cPatient attitudes toward NMOSD diagnosis and treatment: final survey results (4233),\u201d","volume-title":"Poster session presented at: 73rd American Academy of Neurology Annual Meeting","author":"Delgado-Garcia","year":"2021"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000985","article-title":"Pain, depression, and quality of life in neuromyelitis optica spectrum disorder: a cross-sectional study of 166 AQP4 antibody-seropositive patients","author":"Ayzenberg","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.7224\/1537-2073.2017-076","article-title":"Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D","volume":"21","author":"Mealy","year":"2019","journal-title":"Int J MS Care."},{"key":"B23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.msard.2017.07.014","article-title":"Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community","volume":"17","author":"Eaneff","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0177230","DOI":"10.1371\/journal.pone.0177230","article-title":"Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life","volume":"12","author":"Seok","year":"2017","journal-title":"PLoS One."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1001\/jama.286.15.1897","article-title":"The patient-physician relationship. narrative medicine: a model for empathy, reflection, profession, and trust","volume":"286","author":"Charon","year":"2001","journal-title":"JAMA."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e011220","DOI":"10.1136\/bmjopen-2016-011220","article-title":"Research studies on patients' illness experience using the narrative medicine approach: a systematic review","volume":"6","author":"Fioretti","year":"2016","journal-title":"BMJ Open."},{"key":"B27","first-page":"176","article-title":"What is narrative-based medicine? narrative-based medicine 1","volume":"64","author":"Zaharias","year":"2018","journal-title":"Can Fam Physician."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.966428\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T15:49:37Z","timestamp":1662479377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.966428\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":27,"alternative-id":["10.3389\/fneur.2022.966428"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.966428","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"article-number":"966428"}}